Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Molecular Cancer Therapeutics|December 10, 2020
Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells <i>In Vitro</i>Sarah E Kohrt, Wisam N Awadallah, Robert A Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancerRainer Kuefer, Matthias D Hofer, Juergen E Gschwend, et al.
Oncotarget|November 20, 2020
MEK is a promising target in the basal subtype of bladder cancerNathan M Merrill, Nathalie M Vandecan, Kathleen C Day, et al.
The Prostate|May 2, 2020
Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasiaPetra Popovics, Wisam N Awadallah, Sarah E Kohrt, et al.
The Prostate|December 29, 2015
NF-κB and androgen receptor variant expression correlate with human BPH progressionDavid C Austin, Douglas W Strand, Harold L Love, et al.
Molecular Medicine (Cambridge, Mass.)|October 30, 2013
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancerPetros D Grivas, Kathleen C Day, Andreas Karatsinides, et al.
Plos One|October 4, 2011
Repression of androgen receptor transcription through the E2F1/DNMT1 axisConrad David Valdez, Joanne N Davis, Hana M Odeh, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 21, 2014
FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotypeDavid J DeGraff, Magdalena M Grabowska, Tom C Case, et al.
Endocrinology|December 19, 2015
Nfib Regulates Transcriptional Networks That Control the Development of Prostatic HyperplasiaMagdalena M Grabowska, Stephen M Kelly, Amy L Reese, et al.
Neoplasia (New York, N.Y.)|June 8, 2006
ADAM15 disintegrin is associated with aggressive prostate and breast cancer diseaseRainer Kuefer, Kathleen C Day, Celina G Kleer, et al.
Pageof 6